戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 a-antagonists have agonist properties at the beta3-adrenoceptor.
2 e of two active conformational states of the beta3-adrenoceptor.
3 ative beta4-adrenoceptor) that resembles the beta3-adrenoceptor.
4 tive beta4-adrenoceptor is distinct from the beta3-adrenoceptor.
5 drenoceptor is genetically distinct from the beta3-adrenoceptor.
6 in the SAT and very little expression of the beta3-adrenoceptor.
7 rom the other two subtypes difficult and the beta3-adrenoceptor a less-understood subtype.
8 ll proliferation following cold acclimation, beta3-adrenoceptor activation, and burn injury.
9       Administration of the murine-selective beta3 adrenoceptor agonist CL-316,243 corrects obesity a
10 he beta1-adrenoceptor agonist dobutamine and beta3-adrenoceptor agonist BRL 37344A had little effect
11 ater by intra-BAT injections of the specific beta3-adrenoceptor agonist CL316,243 in one pad and the
12 ocal metabolic effects of a highly selective beta3-adrenoceptor agonist in humans.
13            The effects of a highly selective beta3-adrenoceptor agonist on insulin action, energy met
14                                    Cold- and beta3-adrenoceptor agonist-induced sympathetic activatio
15 s, but with limited clinical experience, are beta3 adrenoceptor agonists and phosphodiesterase type 5
16 increased risk of cognitive decline, whereas beta3-adrenoceptor agonists (hereafter, beta3-agonists)
17                                              beta3-Adrenoceptor agonists have recently been introduce
18 ker that causes agonist effects through both beta3-adrenoceptors and cardiac putative beta4-adrenocep
19  for future studies to better understand the beta3-adrenoceptor as a novel pharmacological target.
20 p should lower Na(+) concentrations, and the beta3 adrenoceptor (beta3 AR) mediates pump stimulation
21 ased after activation of adipocyte-expressed beta3 adrenoceptors by catecholamines, and identified eo
22                               Stimulation of beta3-adrenoceptors by selective agonists improves insul
23     First, the ligand-recognition profile of beta3-adrenoceptors differs considerably from that of th
24 er, these experiments suggest that the human beta3-adrenoceptor exists in at least two different agon
25 echanisms of BDNF, muscarinic receptors, and beta3-adrenoceptor expression.
26 agonist effects in mice lacking a functional beta3-adrenoceptor gene (beta3 KO).
27 ociation between the Trp64Arg variant of the beta3-adrenoceptor gene and visceral obesity.
28                                  The role of beta3-adrenoceptor gene polymorphisms has insufficiently
29 ypothesis that postmenopausal women with the beta3-adrenoceptor gene variant (Trp64Arg) have reduced
30 ion, older obese women carrying the Trp64Arg beta3-adrenoceptor gene variant have an impaired capacit
31                                            A beta3 adrenoceptor has been identified and cloned.
32 tagonist affinity measurements varied at the beta3-adrenoceptor in a manner similar to those observed
33 mpathetic ganglia neurons and an increase of beta3-adrenoceptor in the SAT.
34            Second, the expression pattern of beta3-adrenoceptors is more restricted than that of othe
35                                       Third, beta3-adrenoceptors lack the phosphorylation sites invol
36                   Importantly, the effect of beta3-adrenoceptor on mTOR complex 2 is independent of t
37      This article discusses three aspects of beta3-adrenoceptor pharmacology.
38       Alprenolol inhibited fenoterol-induced beta3-adrenoceptor responses while acting as an agonist
39                   In this respect, the human beta3-adrenoceptor seems similar to the human beta1-adre
40 efore examined the pharmacology of the human beta3-adrenoceptor stably expressed in Chinese hamster o
41                                 We show that beta3-adrenoceptors stimulate glucose uptake in brown ad
42 pamycin (mTOR) complex 2 has a novel role in beta3-adrenoceptor-stimulated glucose uptake in brown ad
43                 Both parts are essential for beta3-adrenoceptor-stimulated glucose uptake.
44                            Whether selective beta3-adrenoceptor stimulation exerts metabolic actions
45 onfounding factor in previous studies of the beta3-adrenoceptor Trp64Arg variant and energy expenditu
46                            Their target, the beta3-adrenoceptor, was discovered much later than beta1
47 ity and mRNA levels of IGF-1, TGF-beta1, and beta3-adrenoceptor were increased at days 7 and/or 28.
48 arently differs between the human and rodent beta3-adrenoceptor, yielding considerable species differ